Your session is about to expire
← Back to Search
Tenecteplase (tNK-TPA) for Stroke (AcT Trial)
AcT Trial Summary
This trial will compare two treatments for acute ischemic stroke - intravenous tenecteplase and intravenous alteplase. 1600 patients will be enrolled, and the primary outcome measure is the rate of disability-free survival at 90-120 days.
- Stroke
- Intracranial Thrombosis
AcT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAcT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AcT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Yes, can you tell us about other research that has used Tenecteplase (tNK-TPA)?
"There are 33 on-going clinical trials evaluating Tenecteplase (tNK-TPA), with the majority of these studies being Phase 3 trials. 23 of these trials are based in Beijing, but there are a total of 743 research sites for Tenecteplase (tNK-TPA) across the world."
Are there any open slots in this experiment for new test subjects?
"This particular study is not presently enrolling patients but there are 33 other trials for Tenecteplase (tNK-TPA) that are. If you're seeking other studies, 1280 trials involving wake-up stroke are actively recruiting participants."
Share this study with friends
Copy Link
Messenger